Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P05412 (
c-Jun
)
11,453
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In vivo and in vitro studies revealed that nitroalkenes serve as protective mediators in the lung by inducing the cytoprotective enzyme heme oxygenase-1 (HO-1). Nitrolinoleic acid (
LNO2
) increased HO-1 mRNA, protein, and activity in cultured pulmonary epithelial cells treated with 5 to 50 microM
LNO2
and in lungs of rats injected intraperitoneally with 2.6 mg/kg
LNO2
twice daily for 20 days. Western blotting revealed that HO-1 protein increased significantly within 4 h of in vitro
LNO2
addition and was preceded by an increase in HO-1 mRNA, consistent with transcriptional regulation of HO-1 expression by
LNO2
.
LNO2
also dephosphorylated and activated eukaryotic initiation factor 2alpha, a key translational regulatory protein, indicating that increased translation may also contribute to
LNO2
-induced increases in HO-1. Exposure of cells to
LNO2
activated ERK and JNK, as evidenced by increased phosphorylation. Downstream targets of ERK and JNK, Elk-1 and
c-Jun
, respectively, were also phosphorylated in response to
LNO2
exposure. However, inhibitor studies revealed that only the ERK pathway is necessary for the
LNO2
-mediated increase in HO-1 mRNA and protein. These data reveal that
LNO2
induces pulmonary epithelial HO-1 expression and downstream adaptive responses to inflammation via both transcriptional and translational regulatory mechanisms.
...
PMID:Fatty acid transduction of nitric oxide signaling: nitrolinoleic acid mediates protective effects through regulation of the ERK pathway. 1913 25